Could a simple blood test boost colon cancer screening in appalachia?
NCT ID NCT06119425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether offering a blood test for colorectal cancer screening would be accepted by average-risk patients in Appalachian outpatient clinics. Over 200 participants were given the option of a standard screening method or a blood-based test called Shield. The goal was to see if the blood test improved screening rates and patient willingness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blood-based colorectal cancer screening test (Shield by Guardant Health)
- What this could lead to
- If successful, this could show that a simple blood test makes colorectal cancer screening more acceptable and accessible, potentially increasing early detection in underserved areas.
- What could go wrong
- This is a small, completed implementation study, not a trial proving the test's accuracy or impact on cancer outcomes. Results may not apply to other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER COLON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johnson City Medical Center
Johnson City, Tennessee, 37604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.